At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
BMS-984923drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
In Brief
A Phase 1 clinical trial evaluating BMS-984923 for Alzheimer Disease. Completed, enrolled 36 participants across 1 site.
Detailed Summary
This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartMar 2021
Primary CompletionApr 2022
TodayJul 2026
First PostedMar 18, 2021
Enrollment StartMar 25, 2021
Primary CompletionApr 24, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.3 years ago
Interventions
BMS-984923drug
Day 1: Admission, administration of study drug, and 2 night in-patient stay; Day 3: Discharge following the completion of all scheduled procedures.